185 results
8-K
EX-99.1
RGLS
Regulus Therapeutics Inc
21 Mar 24
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
4:18pm
General and administrative
Total operating expenses
Loss from operations
Other income (expense), net
Loss before income taxes
Income tax expense
Net loss
8-K
EX-10.1
RGLS
Regulus Therapeutics Inc
14 Mar 24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
4:57pm
have not been described as required.
2.21 Tax Liabilities and Reserves. Other than as set forth in the SEC Documents, any tax returns required … file or pay would not result in a Material Adverse Effect on the Company. There is no material proposed tax deficiency, assessment, charge or levy
8-K
EX-3.1
kes3goqw6b6u3
14 Mar 24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
4:57pm
S-8
EX-99.5
j74s6q0me54k
12 Jan 24
Registration of securities for employees
4:11pm
8-K
EX-99.1
m4m1uydto0iu6uqo
9 Nov 23
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
4:15pm
8-K
EX-99.1
anyn13imufc8e840x
8 Aug 23
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
4:15pm
8-K
EX-99.1
b6ceh
14 Jun 23
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.1
80swhk xy055bf1suw
11 May 23
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
4:16pm